Vanguard Group’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-592,305
Closed -$16.6M 4180
2019
Q3
$16.6M Sell
592,305
-99,013
-14% -$1.6M ﹤0.01% 2574
2019
Q2
$9.75M Buy
691,318
+175,605
+34% +$1.67M ﹤0.01% 2871
2019
Q1
$4.58M Buy
515,713
+198,456
+63% +$1.61M ﹤0.01% 3169
2018
Q4
$2.4M Sell
317,257
-302,347
-49% -$4.87M ﹤0.01% 3318
2018
Q3
$13M Buy
619,604
+14,985
+2% +$357K ﹤0.01% 2792
2018
Q2
$18.1M Buy
604,619
+115,200
+24% +$3.14M ﹤0.01% 2606
2018
Q1
$13.3M Buy
489,419
+277,394
+131% +$8.3M ﹤0.01% 2674
2017
Q4
$6.11M Buy
212,025
+45,372
+27% +$1.24M ﹤0.01% 3046
2017
Q3
$4.05M Buy
166,653
+149,153
+852% +$3.54M ﹤0.01% 3197
2017
Q2
$390K Buy
+17,500
New +$368K ﹤0.01% 3769

Vanguard Group's DOVA Position: Q4 2019 in Review

Vanguard Group sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q4 2019, closing a stake of 592,305 shares — an estimated $16.6M sold.

Vanguard Group first reported a position in DOVA in Q2 2017 and held it in 10 quarters. The position peaked at $18.1M in Q2 2018. 0 funds tracked by Wall St. Rank hold DOVA as of Q4 2019.

  • Vanguard Group reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Vanguard Group sold 592,305 Dova Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $16.6M.
  • Vanguard Group first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 10 quarters.
  • Vanguard Group's Dova Pharmaceuticals, Inc. Common Stock position peaked at $18.1M in Q2 2018.
  • 0 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Vanguard Group's 13F filing for Q4 2019, filed 14 Feb 2020.